CancerDrs

Prostate Cancer clinical trials in New Mexico

7 actively recruiting prostate cancer trials at 3 sites across New Mexico.

Data from ClinicalTrials.gov · last refreshed

Phase 3 Recruiting Academic/Other

Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer

This phase III trial compares stereotactic body radiation therapy (SBRT), (five treatments over two weeks using a higher dose per treatment) to usual radiation therapy (20 to 45 treatments over 4 to 9 weeks) for the treatment of high-risk …

Sponsor: NRG Oncology
NCT ID: NCT05946213
Sites in New Mexico:
  • University of New Mexico Cancer Center — Albuquerque, New Mexico
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)

Researchers are looking for new ways to treat metastatic castration-resistant prostate cancer (mCRPC). Researchers have designed a study medicine called ifinatamab deruxtecan (also called I-DXd or MK-2400) to treat mCRPC. The goal of this …

Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06925737
Sites in New Mexico:
  • University of New Mexico Comprehensive Cancer Center ( Site 0022) — Albuquerque, New Mexico
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Castration-resistant Prostate Cancer.

This study will explore whether a combination of the investigational drug PF-06821497 and enzalutamide will work better than taking enzalutamide alone in participants with mCRPC who are ARSi or abiraterone naïve.

Sponsor: Pfizer
NCT ID: NCT06629779
Sites in New Mexico:
  • CHRISTUS St. Vincent Regional Cancer Center — Santa Fe, New Mexico
View on ClinicalTrials.gov →
Phase 2 Recruiting Industry

A Phase 2 Study to Evaluate the Effects of ASP5541 in Participants With Prostate Cancer

Hormone therapy, or androgen deprivation therapy (ADT) is a standard way to treat prostate cancer. It works by reducing the amount of the main male sex hormone, testosterone in the body. Androgen receptor pathway inhibitors (ARPIs) are ano…

Sponsor: Astellas Pharma Global Development, Inc.
NCT ID: NCT07005154
Sites in New Mexico:
  • New Mexico Oncology Hematology Consultants — Albuquerque, New Mexico
View on ClinicalTrials.gov →
Phase 1 Recruiting Industry

A Safety and Dose-finding Study of PRL-02 Depot in Men With Advanced Prostate Cancer

Medicines that reduce the amount of testosterone in the body are commonly used to treat prostate cancer. PRL-02 depot is a potential treatment for men with advanced prostate cancer. It is given by an injection into the muscle. Men with adv…

Sponsor: Astellas Pharma Global Development, Inc.
NCT ID: NCT04729114
Sites in New Mexico:
  • New Mexico Oncology Hematology Consultants Ltd — Albuquerque, New Mexico
View on ClinicalTrials.gov →
Recruiting Industry

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and its clinic…

Sponsor: Massive Bio, Inc.
NCT ID: NCT03452774
Sites in New Mexico:
  • Massive Bio SYNERGY-AI site — Albuquerque, New Mexico
View on ClinicalTrials.gov →
Recruiting Industry

DESTINY-PANTUMOUR04

This study will evaluate the effectiveness of T-DXd in patients with HER2-positive (IHC 3+) locally advanced, unresectable, or metastatic solid tumors who have received prior systemic treatment for metastatic or advanced disease and have n…

Sponsor: AstraZeneca
NCT ID: NCT07124000
Sites in New Mexico:
  • Research Site — Farmington, New Mexico
View on ClinicalTrials.gov →

Medical disclaimer: This page aggregates public ClinicalTrials.gov data. It is not medical advice. Always confirm eligibility and enrollment details with the trial site or your oncologist.

Source: ClinicalTrials.gov API v2 · Last checked: 2026-10-12